Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras proteins are small GTPases that function as molecular switches in cellular signaling, cycling between an inactive GDP-bound state and an active GTP-bound state [Wikipedia, NIH]. They are critical for regulating pathways like MAPK and PI3K, which control cell growth, survival, and differentiation [Dana-Farber, NIH]. Mutations in Ras genes, particularly KRAS, HRAS, and NRAS, are among the most common drivers of human cancer, occurring in approximately 20-30% of all tumors [NIH, BMJ]. These mutations typically lock the protein in a constitutively active state, leading to uncontrolled cell proliferation [Dana-Farber, NIH]. Historically considered "undruggable" due to the lack of traditional binding pockets, recent breakthroughs have led to the development of allele-specific inhibitors like sotorasib and adagrasib, which target the KRAS G12C mutation [BMJ, NIH].
Covalent inhibition of the inactive GDP-bound state of mutant Ras proteins (specifically G12C), allosteric inhibition of the switch II pocket, and inhibition of farnesyltransferase to prevent membrane localization.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rat sarcoma virus oncogene homolog (Ras) (Ras).